Drug Type Small molecule drug |
Synonyms- |
Target |
Action modulators, enhancers |
Mechanism NIS modulators(solute carrier family 5 member 5 modulators), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Endometrial Carcinoma | Phase 2 | United States | 01 Sep 2016 | |
| Multiple Myeloma | Phase 2 | United States | 01 Sep 2016 | |
| endometrial clear cell carcinoma | Phase 1 | United States | 15 Sep 2017 | |
| Endometrial Endometrioid Adenocarcinoma | Phase 1 | United States | 15 Sep 2017 | |
| Endometrial Mixed Carcinoma | Phase 1 | United States | 15 Sep 2017 | |
| Endometrial Undifferentiated Carcinoma | Phase 1 | United States | 15 Sep 2017 | |
| Metastatic endometrial cancer | Phase 1 | United States | 15 Sep 2017 | |
| Recurrent Endometrial Cancer | Phase 1 | United States | 15 Sep 2017 | |
| Relapsed Uterine Corpus Sarcoma | Phase 1 | United States | 15 Sep 2017 | |
| Uterine Corpus Cancer | Phase 1 | United States | 15 Sep 2017 |
Phase 1 | 34 | (Cohort A Dose Level 1) | yngtrpkich = lqtmeuwtvr lykpjyxido (pryetbrzwu, ulyzbomfsv - wcempeohnc) View more | - | 29 Oct 2024 | ||
(Cohort A Dose Level 2) | yngtrpkich = oxbowrqzka lykpjyxido (pryetbrzwu, sqzabkambf - kxlgmphlue) View more | ||||||
Phase 1/2 | 8 | (Healthy Volunteers) | mixvokaxhn(xemxmmlvwg) = ixcvnstgxy fjrkejvmms (ooxnejhfkb, 0.39) View more | - | 17 May 2019 | ||
(Myeloma Patients) | ncorrifiml(ydgbgsbkyi) = ghgypayvab btgffbjzbi (jqfhzhfafb, fmcvlcfieu - aypazkaakp) View more |





